Key Highlights

  • Imugene Limited (ASX:IMU) reported positive Phase 1b azer-cel trial results across CLL/SLL and MZL cohorts.
  • Bell Potter maintained a “2-BUY (SPECULATIVE)” recommendation on IMU on 7 May 2026.
  • IMU shares have declined more than 86% over the past year and are trading near their 52-week low.
  • The company raised AUD 16 million to support ongoing clinical development activities.
  • Azer-cel data has been selected for oral presentation at ASCO 2026 in Chicago.

Imugene Limited (ASX:IMU) has returned to investor focus as the biotechnology company continues advancing its lead CAR T therapy program while its share price trades near a 52-week low.

The stock has experienced an extended period of weakness over the past year, reflecting broader Volatility across speculative biotechnology names and the inherent uncertainty tied to clinical-stage Drug Development. However, some investors may now be assessing whether the disconnect between market valuation and clinical progress could present a longer-term opportunity.

Bell Potter maintained a “2-BUY (SPECULATIVE)” recommendation on Imugene on 7 May 2026, even as the stock continued trading significantly below its 52-week high.

IMU Shares Trade Near Multi-Year Lows

Imugene shares have fallen sharply across multiple timeframes. According to the latest market data, the stock declined 86.57% over the past year and more than 71% on a year-to-date basis.

The stock’s 52-week high stands at AUD 0.850, recorded on 13 May 2025, while the 52-week low of AUD 0.105 was reached on 4 May 2026. The latest trading levels place the company near those lows, with the stock down approximately 87.65% from its last significant peak.

Periods of steep declines often attract speculative interest in biotechnology stocks, particularly when companies continue generating clinical milestones despite market weakness. In IMU’s case, recent operational updates have continued focusing heavily on advancing its lead azer-cel program.

Azer-Cel Clinical Data Continues Advancing

Imugene’s primary focus remains azer-cel (azercabtagene zapreleucel), an allogeneic off-the-shelf CD19 CAR T cell therapy targeting blood cancers.

The company reported updated Phase 1b data during the March 2026 quarter from its CAR T-naive expansion cohort basket study. The trial spans ten US sites and five Australian sites and evaluates patients across multiple CD19-positive B-cell malignancies.

Among the most closely watched results were outcomes in Chronic Lymphocytic Leukaemia / Small Lymphocytic Lymphoma (CLL/SLL), where all four evaluable patients responded to treatment, delivering a 100% overall response rate.

In Marginal Zone Lymphoma (MZL), four out of five evaluable patients responded to therapy, translating into an 80% overall response rate, including complete and partial responses.

The company noted that these patients had already undergone multiple prior lines of therapy before entering the study.

Trial Expansion Adds New Combination Arm

Imugene also amended the Phase 1b protocol to include a Bruton Tyrosine Kinase inhibitor (BTKi) combination arm and added Mantle Cell Lymphoma (MCL) as an additional indication.

The BTKi combination arm is designed to enrol patients who previously failed BTKi therapies, which remain established treatments across several B-cell malignancies including CLL, MCL, MZL, and Waldenström's Macroglobulinemia.

Management highlighted that the global BTKi market reached approximately US$12 billion in 2025, underscoring the commercial relevance of this treatment area.

The company stated it will continue prioritising indications showing the strongest clinical data rather than pursuing all potential indications simultaneously.

Strategic Focus Shifts Toward Lead Assets

During the quarter, Imugene confirmed it would cease active development of its CF33 (VAXINIA) program to focus Capital allocation toward higher-priority opportunities led by azer-cel.

The move reflects a broader strategy aimed at concentrating financial and operational resources around programs viewed as having the strongest near-term development potential.

Imugene also strengthened its Balance Sheet through a AUD 16 million capital raising from institutional and retail shareholders. At 31 March 2026, the company held cash and cash equivalents of AUD 5.963 million following receipt of the first Tranche of funds.

Additionally, the company received an R&D tax refund totalling AUD 2.74 million for the 2025 financial year.

ASCO Presentation Adds Visibility

Further visibility for the azer-cel program is expected later this month after the therapy was selected for an oral presentation at ASCO 2026, scheduled between 29 May and 2 June in Chicago.

ASCO remains one of the most closely followed oncology conferences globally, often serving as an important platform for biotechnology companies presenting clinical data to investors, clinicians, and industry participants.

The full abstract for the presentation is expected to be published on 21 May 2026.

Investor Attention Returns to High-Risk Biotech Opportunities

Clinical-stage biotechnology companies often experience significant share-price volatility as investors weigh funding requirements, trial outcomes, regulatory pathways, and commercialisation prospects.

For Imugene, the combination of depressed share-price levels, continued clinical progress, and broker support appears to be placing the company back on speculative investor watchlists.

While risks associated with early-stage biotechnology development remain elevated, some Market Participants may view periods near 52-week lows as potential entry points when operational milestones continue progressing.

About the Company

Imugene Limited (ASX:IMU) is a clinical-stage immuno-oncology company focused on developing cancer therapies including CAR T cell therapies and immunotherapies targeting multiple forms of cancer. The company’s lead program, azer-cel, is currently progressing through Phase 1b clinical evaluation across several B-cell malignancies.